Position statement addresses glucose-lowering agents in type 2 diabetes, ensuring accurate treatment guidance.
In Table 1 "Properties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus" vildagliptin was incorrectly assigned footnote "a" (Limited use in the U.S./Europe) instead of footnote "b" (Not licensed in the U.S.).The online version reflects these changes.
No takes yet. Share an insight, caveat, or question.
Inzucchi et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: